JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 100.3 Billion KRW | 53.68% |
| 2022 | 62.96 Billion KRW | 101.8% |
| 2021 | 31.19 Billion KRW | 669.76% |
| 2020 | -5.47 Billion KRW | 71.2% |
| 2019 | -19.01 Billion KRW | -188.09% |
| 2018 | 21.58 Billion KRW | -0.62% |
| 2017 | 21.71 Billion KRW | -11.49% |
| 2016 | 24.53 Billion KRW | 14.0% |
| 2015 | 21.52 Billion KRW | 18.86% |
| 2014 | 18.1 Billion KRW | -30.08% |
| 2013 | 25.9 Billion KRW | 173.03% |
| 2012 | 9.48 Billion KRW | -42.94% |
| 2011 | 16.62 Billion KRW | -43.0% |
| 2010 | 29.16 Billion KRW | -21.57% |
| 2009 | 37.18 Billion KRW | 1.39% |
| 2008 | 36.67 Billion KRW | -11.12% |
| 2007 | 41.26 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 26.26 Billion KRW | -20.31% |
| 2024 Q2 | 11.63 Billion KRW | -55.68% |
| 2023 Q3 | 26.1 Billion KRW | 26.89% |
| 2023 Q2 | 20.57 Billion KRW | 1.23% |
| 2023 Q1 | 20.32 Billion KRW | -29.14% |
| 2023 FY | 96.76 Billion KRW | 53.68% |
| 2023 Q4 | 32.95 Billion KRW | 26.23% |
| 2022 Q4 | 28.68 Billion KRW | 148.2% |
| 2022 FY | 62.96 Billion KRW | 101.8% |
| 2022 Q1 | 13.32 Billion KRW | 8.66% |
| 2022 Q2 | 9.4 Billion KRW | -29.42% |
| 2022 Q3 | 11.55 Billion KRW | 22.9% |
| 2021 Q1 | 9.36 Billion KRW | 113.84% |
| 2021 Q2 | 2 Billion KRW | -78.6% |
| 2021 Q3 | 7.56 Billion KRW | 277.65% |
| 2021 FY | 31.19 Billion KRW | 669.76% |
| 2021 Q4 | 12.26 Billion KRW | 61.99% |
| 2020 Q4 | 4.38 Billion KRW | 3431.84% |
| 2020 Q1 | -453.65 Million KRW | 98.3% |
| 2020 FY | -5.47 Billion KRW | 71.2% |
| 2020 Q3 | 124.02 Million KRW | 102.31% |
| 2020 Q2 | -5.37 Billion KRW | -1084.53% |
| 2019 Q1 | 3.63 Billion KRW | 135.52% |
| 2019 FY | -19.01 Billion KRW | -188.09% |
| 2019 Q2 | 1.4 Billion KRW | -61.31% |
| 2019 Q4 | -26.69 Billion KRW | -1109.05% |
| 2019 Q3 | 2.64 Billion KRW | 88.22% |
| 2018 Q4 | -10.22 Billion KRW | -146.72% |
| 2018 Q3 | 21.89 Billion KRW | 451.33% |
| 2018 Q2 | 3.97 Billion KRW | -33.25% |
| 2018 Q1 | 5.94 Billion KRW | 37.88% |
| 2018 FY | 21.58 Billion KRW | -0.62% |
| 2017 Q4 | 4.31 Billion KRW | -26.32% |
| 2017 Q3 | 5.85 Billion KRW | 61.15% |
| 2017 Q2 | 3.63 Billion KRW | -54.08% |
| 2017 Q1 | 7.91 Billion KRW | 8.36% |
| 2017 FY | 21.71 Billion KRW | -11.49% |
| 2016 Q3 | 4.36 Billion KRW | -16.63% |
| 2016 Q2 | 5.24 Billion KRW | -31.26% |
| 2016 Q1 | 7.62 Billion KRW | 52.24% |
| 2016 FY | 24.53 Billion KRW | 14.0% |
| 2016 Q4 | 7.3 Billion KRW | 67.15% |
| 2015 Q1 | 5.73 Billion KRW | -12.16% |
| 2015 Q4 | 5 Billion KRW | -7.38% |
| 2015 Q3 | 5.4 Billion KRW | 0.64% |
| 2015 Q2 | 5.37 Billion KRW | -6.33% |
| 2015 FY | 21.52 Billion KRW | 18.86% |
| 2014 FY | 18.1 Billion KRW | -30.08% |
| 2014 Q4 | 6.53 Billion KRW | 8.61% |
| 2014 Q3 | 6.01 Billion KRW | 377.21% |
| 2014 Q2 | -2.16 Billion KRW | -128.04% |
| 2014 Q1 | 7.73 Billion KRW | 49.25% |
| 2013 Q4 | 5.18 Billion KRW | -18.39% |
| 2013 FY | 25.9 Billion KRW | 173.03% |
| 2013 Q1 | 5.64 Billion KRW | 104.26% |
| 2013 Q2 | 8.72 Billion KRW | 54.53% |
| 2013 Q3 | 6.35 Billion KRW | -27.19% |
| 2012 Q4 | 2.76 Billion KRW | -26.86% |
| 2012 FY | 9.48 Billion KRW | -42.94% |
| 2012 Q3 | 3.77 Billion KRW | 282.0% |
| 2012 Q1 | 5.35 Billion KRW | 0.0% |
| 2012 Q2 | -2.07 Billion KRW | -138.75% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 7.9 Billion KRW | 15.89% |
| 2011 Q1 | 6.81 Billion KRW | 20.59% |
| 2011 Q3 | 5.99 Billion KRW | -24.16% |
| 2011 FY | 16.62 Billion KRW | -43.0% |
| 2010 Q4 | 5.65 Billion KRW | 121.12% |
| 2010 FY | 29.16 Billion KRW | -21.57% |
| 2010 Q1 | 11.07 Billion KRW | 3.74% |
| 2010 Q3 | 2.55 Billion KRW | -74.12% |
| 2010 Q2 | 9.87 Billion KRW | -10.81% |
| 2009 Q2 | 9.75 Billion KRW | -21.63% |
| 2009 Q4 | 10.67 Billion KRW | 148.6% |
| 2009 Q3 | 4.29 Billion KRW | -56.0% |
| 2009 Q1 | 12.45 Billion KRW | 188.7% |
| 2009 FY | 37.18 Billion KRW | 1.39% |
| 2008 Q2 | 13.26 Billion KRW | 14.6% |
| 2008 Q3 | 7.51 Billion KRW | -43.32% |
| 2008 FY | 36.67 Billion KRW | -11.12% |
| 2008 Q4 | 4.31 Billion KRW | -42.63% |
| 2008 Q1 | 11.57 Billion KRW | 157.89% |
| 2007 Q4 | 4.48 Billion KRW | -39.09% |
| 2007 Q1 | 14.17 Billion KRW | 0.0% |
| 2007 Q2 | 15.23 Billion KRW | 7.5% |
| 2007 FY | 41.26 Billion KRW | 0.0% |
| 2007 Q3 | 7.36 Billion KRW | -51.63% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -27415.38% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | -30.465% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 226.07% |
| HANDOK Inc. | 12.57 Billion KRW | -697.401% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 5142.562% |
| Yuhan Corporation | 74.56 Billion KRW | -34.523% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -797.295% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 655.93% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 55.398% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -3182.127% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -598.96% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -16718.125% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -10307.489% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -271.063% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -27415.38% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 1393.232% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -2386.688% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 243.393% |
| JW Holdings Corporation | 143.66 Billion KRW | 30.182% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 287.773% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 59.325% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 311.645% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -1348.026% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -1450.044% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -1048.773% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -27415.38% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -105.677% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 24.814% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 0.0% |
| Yuhan Corporation | 74.56 Billion KRW | -34.523% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -379.459% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -3117.551% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -133.292% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -389.66% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -82.537% |
| CKD Bio Corp. | -20.15 Billion KRW | 597.723% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -211.185% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -296.425% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -208.389% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 311.645% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -202.604% |
| Boryung Corporation | 68.26 Billion KRW | -46.929% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 367.5% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -598.96% |
| JW Lifescience Corporation | 32.09 Billion KRW | -212.556% |